entertainment -WSS

entertainment

author：knowledge 2025-09-28 07:22:06 - browse：12944

Red blood cells flow in an artery biotech — coverage from STAT — Adobe

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients.

Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen Pharmaceuticals.

The treatment, injected monthly, also reduced the risk of major bleeding events by 74% and gastrointestinal bleeding by 93%, according to Phase 2 results presented here Sunday at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： How housing is health care on Long Island

WSS

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

Churchill Downs extends trainer Bob Baffert's ban through 2024

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

Generate Biomedicines machine learning biotech raises $273M

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

White House touts steps to stem shortages of cancer treatments

explore

entertainment

focus

In Memoriam: Notable people who died in 2023

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

Medical records are filled with copy

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

New weight loss drugs vying to be the next Wegovy or Mounjaro

Duchenne breakthrough therapy leaves behind pioneering families

New weight loss drugs vying to be the next Wegovy or Mounjaro

Anesthesiologist group: stop taking Ozempic before surgery

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

focus

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

FDA panel endorses Alnylam’s heart drug — after picking it apart

US judge blocks portions of new Florida elections law

Walmart eyes Medicare Advantage provider ChenMed

Noem? Reynolds? A very early look at the Republican 'veepstakes'

White House touts steps to stem shortages of cancer treatments

knowledge

leisure time

knowledge

entertainment